Studies from St. Joseph's Hospital Add New Findings in the Area of Adenocarcinoma (Current State of Prognostication, Therapy and Prospective Innovations for Barrett's-related Esophageal Adenocarcinoma: a Literature Review)

摘要

2021 SEP 23 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - New research on Oncology - Adenocarcinoma is the subject of a report. According to news reporting originating in Phoenix, Arizona, by NewsRx journalists, research stated, "Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), which has one of the lowest 5-year survival rates in oncology. The reasons for poor survival are twofold: the large majority of diagnoses are in advanced stages ( 80%) and limited treatment options, with a deficit of biology-guided therapies." The news reporters obtained a quote from the research from St. Joseph's Hospital, "As a rapidly growing public health concern with poor prognosis, research into the molecular progression for BE and novel therapeutics for EAC currently has high clinical utility. Review of the literature reveals that innovative analysis of metaplastic progression from BE to EAC at a molecular level can shed light on the underlying transformative probabilities of BE into malignant pathologies and may impact current of future t Background: EAC is the fastest increasing cancer in the United States with a 600% increase over the past 25 years.